Myriad Genetics and Lumea Collaborate to Enhance Access to the Prolaris Biomarker and MyRisk Hereditary Cancer Tests through BxLink Integration
1. Myriad and Lumea will integrate advanced diagnostic tests into digital pathology. 2. Prolaris and MyRisk tests aim to improve cancer treatment decisions. 3. Integration reduces errors and speeds up test results under 10 days. 4. Collaboration expected to enhance patient outcomes and streamline physician workflows. 5. Myriad's tests included in NCCN guidelines improve treatment strategies.